Emergent BioSolutions plant in Baltimore, USA: Breakdown in production
Photo: SAUL LOEB / AFP
A manufacturing defect in the vaccine from Johnson & Johnson now apparently calls the US FDA on the plan. This has called for a production stop in the affected plant in the USA, as the company Emergent BioSolutions announced in a message to the US Securities and Exchange Commission. Emergent BioSolutions operates the Baltimore, Maryland facility. Accordingly, the FDA has requested that production be suspended until an ongoing investigation has been completed.
The US pharmaceutical company Johnson & Johnson had confirmed at the end of March that a batch of its vaccine in the production facility in Baltimore "did not meet the quality requirements".
Johnson & Johnson did not provide any numbers themselves.
According to the New York Times, 15 million vaccine doses were unusable because employees accidentally mixed up the ingredients in two vaccines.
The Baltimore facility produces vaccines for both Johnson & Johnson and AstraZeneca.
Johnson & Johnson announced that it would deliver an additional 24 million cans in April despite the glitch.
The vaccine received emergency approval in the United States in late February.
The vaccine was then also approved in the EU in mid-March.
Unlike in the USA, the vaccine is not yet in use in the European Union.
Last week, vaccinations with the vaccine in the USA were temporarily stopped after isolated cases of severe blood clots.
The delivery of the vaccine to Europe has also been postponed.
The European Medicines Agency (EMA) announced its updated assessment of the safety of Johnson & Johnson's corona vaccine on Tuesday afternoon.
Unlike the other corona vaccines approved to date, the Johnson & Johnson vaccine only requires one injection syringe for comprehensive protection.
In addition, storage and delivery are comparatively easy.
The vaccine was therefore increasingly used in the United States.
So far, according to updated data, more than 7.2 million doses of the vaccine have been injected in the United States.
The far greater part of the vaccinations were carried out with the active ingredients of the US companies Moderna and Pfizer with its German partner Biontech, these preparations are still used.
In the USA, an advisory body to the US health authority CDC wants to advise next Friday on how to proceed with the Johnson & Johnson vaccine.
No decision on a possible continuation, lifting or partial lifting of the vaccination ban in the USA is expected before a recommendation by the "Advisory Committee on Immunization Practices" (ACIP).
mmq / AFP